OUTSIDE REVIEWS OF DRUG SAFETY AND EFFICACY DATA
This article was originally published in The Tan Sheet
Executive Summary
OUTSIDE REVIEWS OF DRUG SAFETY AND EFFICACY DATA is an issue that is likely to be revisited in the upcoming Congress as the newly dominant Republican party reasserts its anti-regulatory agenda. Another GOP priority is emphasizing safety over efficacy in evaluating new products and placing more reliance on post- approval data. The European system of drug evaluation is a likely model for consideration, Hill staffers said.